Cellvizio by Mauna Kea Technologies

Cellvizio by Mauna Kea Technologies Cellvizio is the real-time in vivo cellular imaging platform that revolutionizes the way physicians

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real-time, classify indeterminate areas of concern, and guide sur

gical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is revolutionizing the way physicians diagnose and treat patients — making a transformative change in medicine.

Advancement in early esophageal cancer detection could significantly impact global health outcomes! This study demonstra...
04/27/2026

Advancement in early esophageal cancer detection could significantly impact global health outcomes! This study demonstrates how is empowering deep learning models to detect esophageal cancer with incredible accuracy. Our breakthrough technology highlights the potential to transform diagnostics by enabling earlier diagnoses and better outcomes.

Learn more about the study: https://hubs.la/Q04dz2Cg0

04/22/2026

We are proud to share a transformative 2025 for Cellvizio by Mauna Kea Technologies marked by a fundamental reset of our balance sheet and reaccelerating organic growth. With a 70% reduction in financial debt and record U.S. sales, our performance underscores the strengthening global impact of .

This momentum has already extended into a record-breaking start to 2026, validating our trajectory toward profitability and our mission to provide life-changing care to patients worldwide.

Read the full PR: https://hubs.la/Q04d5l460

April is (EAC). Chronic GERD can silently progress to Barrett's Esophagus and without precise, targeted imaging, early...
04/21/2026

April is (EAC). Chronic GERD can silently progress to Barrett's Esophagus and without precise, targeted imaging, early cellular changes can be missed until cancer develops.

Advanced imaging via provides real-time, cellular-level visualization during upper endoscopy, helping gastroenterologists identify dysplastic changes earlier, target biopsies more precisely, and make more confident surveillance decisions.

Explore the Barrett's imaging solution: https://hubs.la/Q04cNST20

ECAN Esophageal Cancer Action Network

04/19/2026

Today is . For the millions living with Irritable Bowel Syndrome ( ), this day is a reminder that their symptoms are real, their struggles are valid, and that science is working to provide better answers.

New multi-disciplinary approaches like powered by , are helping clinicians move beyond symptom-based diagnosis toward objective, cellular-level insights.

https://hubs.ly/Q04crSZG0

We are proud to share that we report a strong start to the year with our Q1 2026 financial results. This performance und...
04/15/2026

We are proud to share that we report a strong start to the year with our Q1 2026 financial results. This performance underscores the growing global adoption of and the tangible results of our strategic investments in .

"This momentum reinforces the growing evidence of clinical and commercial adoption of Cellvizio, as the standard of care for the evaluation of pancreatic cysts and subsequent management of patients at risk for pancreatic cancer." - Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies

Read the full PR: https://hubs.la/Q04cchlb0

April is . Millions of people are trapped in a cycle of disruptive symptoms. Affecting up to 12% of the US population...
04/13/2026

April is . Millions of people are trapped in a cycle of disruptive symptoms. Affecting up to 12% of the US population, this condition often persists for over a decade, frequently going undiagnosed by standard tests.

End the guesswork for your patients. With the test, you can visualize live cell-responses at the mucosal barrier to help identify food triggers with clinical precision.

Visit: https://hubs.la/Q04bCMvM0 to learn more.

04/09/2026

Join one of our on-site workshops with live cases to gain the latest insights into , led by nCLE expert Bertrand Napoléon, MD at Ramsay Santé.

To attend one of these Live Cases event, sign up here:
https://hubs.la/Q04bbzV00

This , we’re uniting under a singular mission: Together for health. Stand with science. innovation sits at the heart o...
04/07/2026

This , we’re uniting under a singular mission: Together for health. Stand with science.

innovation sits at the heart of this mission. When physicians have access to advanced visualization tools like , patients everywhere benefit. From improving early cancer detection to reducing unnecessary procedures, cellular imaging is advancing health equity one ddecision at a time.

Learn More: https://hubs.la/Q049Jdw80

We are proud to spotlight the groundbreaking work of leading gastroenterologists who are pushing the boundaries of diagn...
04/02/2026

We are proud to spotlight the groundbreaking work of leading gastroenterologists who are pushing the boundaries of diagnostic precision with .

Experts are actively integrating Cellvizio into their clinical practice sharing insights on how real-time cellular imaging is transforming patient management across pancreatic cysts, Barrett's Esophagus, and beyond.

Tag a GI colleague who is advancing the field! 👇

04/02/2026

First cases at Midwest Digestive Health and Nutrition. Thank you to Dr. Aashesh Verma and his team for their commitment to personalized care and helping their patients who have struggled to find relief. With real-time microscopic results, CellTolerance, powered by , provides the clarity to identify which foods trigger a patient’s food-related symptoms and just as importantly, which ones do not.

From gastroenterology to pulmonology, the platform supports physicians across a broad range of clinical indications.Im...
03/31/2026

From gastroenterology to pulmonology, the platform supports physicians across a broad range of clinical indications.

Improve risk-stratification for pancreatic cysts. Increase Barrett's Esophagus detection. Help characterize lung nodules. All through real-time, in vivo cellular imaging at the point of care.

One platform built for precision. Multiple specialities.

Explore the full range: https://hubs.la/Q0493vk40

Advances in nCLE combined with artificial intelligence are improving real-time pancreatic cyst evaluation.The study rein...
03/26/2026

Advances in nCLE combined with artificial intelligence are improving real-time pancreatic cyst evaluation.

The study reinforces that nCLE enables high-resolution imaging for better risk stratification, while AI improves sensitivity for detecting advanced neoplasia and reduces review time by automating identification. By standardizing interpretation and improving key architectural features, this approach supports more precise clinical decision-making.

Full article: https://hubs.la/Q0483v4k0

Address

24 Denby Road, Suite 140
Boston, MA
02134

Opening Hours

Monday 8:30am - 5pm
Tuesday 8:30am - 5pm
Wednesday 8:30am - 5pm
Thursday 8:30am - 5pm
Friday 8:30am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Cellvizio by Mauna Kea Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Our Story

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.